Related Experiment Video
Updated: Aug 6, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease
Teresita Reiner1, Alicia de las Pozas, Carlos Perez-Stable
1Department of Medicine and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Background:
We investigated whether sequential combinations of flavopiridol and docetaxel can increase apoptotic cell death and inhibit the growth of primary and metastatic prostate tumors in the Ggamma/T-15 transgenic mouse model of prostate cancer.
Methods:
Transgenic males were treated and the weights of primary and metastatic prostate tumors determined. Immunohistochemistry and Western blot was performed to evaluate the differences in apoptosis, proliferation, and angiogenesis.
Results:
Docetaxel was slightly more effective than flavopiridol in inhibiting primary prostate tumors, but neither drug alone inhibited metastases. Single drug treatments decreased angiogenesis but did not increase apoptosis. Both sequential combinations resulted in greater inhibition of primary and metastatic prostate tumors, increased apoptosis, and decreased angiogenesis compared to control mice.
Conclusions:
Flavopiridol and docetaxel sequence combinations were effective in inhibiting prostate tumors in the Ggamma/T-15 transgenic mice. An increase in apoptosis and a decrease in angiogenesis resulted in the greatest inhibition of prostate cancers.
Insights
Sequential combinations of flavopiridol and docetaxel effectively inhibited prostate tumors in mice. This approach increased cancer cell death (apoptosis) and reduced new blood vessel formation (angiogenesis), leading to greater tumor inhibition.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
- Investigating drug combinations for enhanced efficacy in prostate cancer treatment is crucial.
Purpose of the Study:
- To evaluate the efficacy of sequential flavopiridol and docetaxel combinations against prostate tumors.
- To determine the impact of these combinations on tumor growth, apoptosis, and angiogenesis.
Main Methods:
- Utilized the Ggamma/T-15 transgenic mouse model of prostate cancer.
- Administered sequential combinations of flavopiridol and docetaxel.
- Assessed primary and metastatic tumor weights, apoptosis, proliferation, and angiogenesis via immunohistochemistry and Western blot.
Main Results:
- Neither flavopiridol nor docetaxel monotherapy inhibited metastatic prostate tumors.
- Sequential combinations significantly inhibited both primary and metastatic prostate tumors.
- Combined treatments increased apoptosis and decreased angiogenesis compared to controls.
Conclusions:
- Sequential administration of flavopiridol and docetaxel demonstrates significant efficacy in inhibiting prostate tumors.
- The observed therapeutic effect is attributed to increased apoptosis and reduced angiogenesis.
- This combination therapy represents a promising strategy for prostate cancer treatment.
